Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Individual Bioequivalence Interim Approach Proposed To Gather More Data

Executive Summary

An expert panel assembled by FDA is proposing that the agency adopt an interim approach to new bioequivalence methods, panel member Leslie Benet, PhD, University of California(San Francisco, told an American Association of Pharmaceutical Scientists workshop held March 16-18 in Arlington, Va.

You may also be interested in...

Individual BE Replicate Study Design To Be Analyzed Over Two Years By FDA

FDA is planning to conduct a two-year evaluation of its recommended replicate design method to determine whether a transition away from average bioequivalence criterion and towards individual and population BE criteria should occur.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts